title: In-vitro microbiological assessment of a new penem, Men 10700.
abstract: The in-vitro antibacterial activity of Men 10700, a novel penem, has been compared with that of ritipenem, ciprofloxacin, amikacin, cefotaxime and co-amoxiclav against 539 strains taken from 17 genera. Men 10700 was most active against staphylococci and streptococci (MIC90 < 0.5 mg/L), slightly less active against Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Citrobacter spp., Moraxella catarrhalis and peptostreptococci (MIC90 0.5-2 mg/L), moderately active against Enterococcus faecalis, members of the tribe Proteae, Serratia marcescens, Acinetobacter spp., clostridia and Bacteroides spp. (MIC90 4-16 mg/L), and inactive against Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Enterococcus faecium. Its antibacterial spectrum is thus slightly less broad than that of imipenem, but it compares favourably with an oral third-generation cephalosporin. Men 10700 was more active than ritipenem against many species, especially Enterobacter spp. and Citrobacter spp.
authors.affiliation: Department of Medical Microbiology, Royal Free Hospital School of Medicine, London, UK.
authors.forename: J M
authors.initials: JM
authors.lastname: Hamilton-Miller
authors.forename: S
authors.initials: S
authors.lastname: Shah
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D007769:Lactams; D008826:Microbial Sensitivity Tests
chemical_list: D000900:Anti-Bacterial Agents; D007769:Lactams; C106870:Men 10700